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Abstract
Background: Plasmablastic lymphoma (PBL) is relatively new clinical entity described as a distinct subtype of diffuse large
B-cell lymphoma (DLBCL). It is characterized by its aggressive nature and proliferation of large neoplastic cells resembling
immunoblasts including cells with more obvious plasmacytic differentiation. In this case report, we describe an unexpected
finding of PBL associated with a mature cystic teratoma of the ovary in a young immune competent woman.
Case presentation: A 19-year old woman was admitted to the hospital with generalized lymphadenopathy, a pelvic
tumor mass measuring 35 × 30 cm and a 4 cm lump in her right breast. She underwent a right salpingo-oophorectomy,
lymphadenectomy, splenectomy, omentectomy, and a right breast lumpectomy. On macroscopic examination the right
ovary was replaced by a thick-walled multilocular cystic tumor. Upon incision, the cysts were filled with thick, greasy
sebaceous material and hair and there were several solid nodules within the cyst walls. Histological examination revealed
a mature cystic teratoma and malignant non-Hodgkin lymphoma (NHL) within the solid nodules. Tumor tissue from the
right breast, spleen and lymph nodes, all had the same histological, NHL morphology. After extensive immunostaining, a
diagnosis of PBL was made. Following surgery, the patient was treated with different chemotherapy regimens, without
any significant regression of the disease, and died of multiple organ failure.
Conclusions: Primary NHL of the ovary is relatively rare occurrence while secondary involvement by lymphoma is much
more common. PBL is a rare lymphoma, primarily reported in the jaw and oral mucosa, but also documented in extra-oral
sites. To the best of our knowledge, this is the first case described in a mature ovarian cystic teratoma. Although the patient
was HIV-negative and immune competent, she had progressive disease and died despite aggressive chemotherapy
11 months after the initial diagnosis.
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Background
Plasmablastic lymphoma (PBL) is a rare and aggressive
variant of NHL with diffuse proliferation of large neoplastic
cells with cytomorphological features that resemble B
immunoblasts, but with the immunophenotype of the
plasma cells [1]. In the most cases, this neoplasm occurs in
the oral cavity of HIV-positive patients. Other immunodefi-
ciency states such as iatrogenic immune suppression in
treatment of autoimmune diseases or chemotherapy are
also associated with this diagnosis [1, 2]. It is primarily an
adult disease that occurs most frequently around 50 years
of age, affecting men more often than women. Although,
the majority of patients are adults, it has also been reported
in the pediatric age group [3]. Involvement of extra-oral
sites, such as the orbit, sinonasal cavity, gastrointestinal
tract, soft tissues, liver, retroperitoneal region and bone can
also be found, especially in PBLs that are not associated
with HIV infection [3]. The PBL cells are usually positive
for a plasma cell phenotype including CD138, CD38,
CD79a, IRF4/MUM1, cytoplasmic immunoglobulins (most
frequently IgG) and either kappa or lambda light chain with
a high Ki-67 proliferation index (usually ≥80%) [2, 3].
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Approximately 70% of cases express EBV-encoded RNA
(EBER), which is the most sensitive methodology for
detecting EBV infection within the malignant cells [2]. Both
HIV-positive and HIV-negative patients are at advanced
clinical stage (Ann-Arbour III or IV) on presentation. This
rare clinical entity represents a diagnostic challenge due to
its specific morphological and immunohistochemical
resemblance to lymphomas with plasmablastic differenti-
ation, more precisely plasmablastic or anaplastic multiple
myleoma. Furthermore, with its aggressive clinical course
and almost 100% rate of death within the first year of diag-
nosis, it also remains a therapeutic challenge. This report
presents a very unusual case of PBL in an immune compe-
tent, HIV-negative, 19-year old woman, that was detected
within the walls of an ovarian cystic teratoma occurring as
a part of systemic disease with involvement of the breast,
spleen and lymph nodes.
Case presentation
A 19-year old female was referred to the Department of In-
ternal Medicine for workup of anemia. She complained of
having fever (up to 38 °C), night sweats, dyspnea, dry cough,
and fatigue. Symptoms had been present for 4 weeks and
had not improved after a course of antibiotics prescribed by
her family physician. On physical examination, a palpable
painless mass was noticed in her right abdomen, with
enlarged inguinal lymph nodes as well as a palpable lump in
the right breast with ipsilateral axillary lymphadenopathy.
Abdominal ultrasound (US) examination revealed a multilo-
culated cystic mass with solid areas measuring 35 × 30 cm
in her pelvis. The US examination also showed an enlarged
spleen with enlarged para-aortal lymph nodes. Subsequently,
a thoracic, abdominal and pelvic multi-slice computed tom-
ography scan (MSCT) was performed and showed a well
circumscribed, solid nodule, 4 cm in diameter, in the upper
outer quadrant of right breast with enlarged ipsilateral
axillary lymph nodes, along with generalized abdominal
lymphadenopathy, an enlarged spleen with diffuse multiple
nodal masses and a complex right pelvic tumor mass with
amorphous calcification similar to tooth formation. Based
on the MSCT scan, a tentative diagnosis of an immature
teratoma was made. The patient proceeded to surgery for a
unilateral right salpingo-oophorectomy, lymphadenectomy,
splenectomy, omentectomy and right breast lumpectomy.
Intraoperative peritoneal washing revealed a poorly differen-
tiated malignant tumor on cytology.
On macroscopic examination, the right ovary was
replaced by a cystic mass with a glistening surface, meas-
uring 17 cm in diameter (Fig. 1a). On incision, the cyst
was partly filled with fatty material and hair. The wall of
the cyst was thickened with solid, grayish nodules. The
spleen was diffusely infiltrated with grayish nodes as
well, measuring up to 4.5 cm in diameter (Fig. 1b).
There was a lobulated, well circumscribed solid, grayish
nodule identified on lumpectomy of the breast. On
histological examination, the cavity of the cyst was lined
by skin with dermal appendages as well as respiratory
type of epithelium, smooth muscle, mature adipose and
bone tissue. This morphology was in agreement with a
diagnosis of mature cystic teratoma of the ovary. Solid
nodules within cyst walls were tumor tissue, with a
diffuse growth pattern, composed of large polymorphic
cells with vesicular nuclei, a high nuclear-cytoplasmic
ratio, and one or more prominent nucleoli. Some cells
had eccentrically positioned nuclei with a cytoplasmic
halo resembling plasmablasts. The tumor tissue from
the right breast and spleen had the same histological
appearance. An extensive immunohistochemical evalu-
ation was performed. Tumor cells were negative for
panCK, AFP, PLAP, CD117, D2-40, CD30, MyoD1,
HMB45, desmin and CD99, but positive for LCA, EMA
and vimentin. Therefore, a diagnosis of NHL was made.
Subsequent immunohistochemistry showed tumor cells
to be CD79a, PAX5, MUM-1, CD38, CD138 positive
and CD20, CD10, Bcl-6, ALK, cyclin D1, CD56 negative.
Ki-67 was high, around 80% and EBER in situ
hybridization was negative (Fig. 2). According to the
morphological and immunohistochemical findings a
diagnosis of PBL was made. Based on the clinical find-
ings, the patient was staged, Ann-Arbour IV PBL.
Laboratory data showed anemia, normal platelet and
leucocyte counts with elevated lactate dehydrogenase
(LDH), aspartate aminotransferase (AST) and C-reactive
protein (CRP). Serum alpha-1-fetoprotein and human
chorionic gonadotropin were normal while carbohydrate
antigen 125 was increased. Urine analysis and renal
function were within normal limits. Serum immuno-
globulin levels were within normal limits, without
evidence of monoclonal gammopathy and serology was
negative for HIV, HBV and HCV. The patient was
transferred to the Hematology ward and treated with
dose-adjusted etoposide, prednisone, vincristine, cyclo-
phosphamide, and doxorubicin (DA-EPOCH) as well as
intra-thecal EPOCH with each cycle [2, 4]. After 4 cycles
of chemotherapy, the patient subjectively felt better
however evaluation with positron emission tomography
and computed tomography scans (PET-CT) showed high
activity of disease. An autologous peripheral blood stem
cell transplantation was planned and 1 cycle of salvage
chemotherapy was given according to DHAP protocol
(cisplatin, cytarabine and dexamethasone). Unfortu-
nately, her underlying disease continued to progress and
4 cycles of alternating modified CODOX-M and IVAC
chemotherapy (cyclophosphamide, vincristine, doxorubi-
cin, high-dosemethotrexate/ifosfamide, etoposide, and
high-dosecytarabine) were given. Autologous stem cell
transplantation could no longer be performed due to
patient’s clinical deterioration. After the fourth cycle of
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chemotherapy, PET-CT scan was performed again, and
revealed profound disease progression. The patient also
had developed treatment complications, such as second-
ary anemia, thrombocytopenia, sepsis, enterocolitis,
ileus, pleural effusions and ascites. Due to the worsening
of the patient’s physical condition, her goals of care were
changed and only supportive therapy was given. The
patient died of multiple organ failure approximately
11 months after initial diagnosis (Additional file 1).
Discussion
PBL was originally reported exclusively in the jaw and oral
mucosa of male, predominantly HIV-positive, patients [5].
It may be present in patients who are HIV-negative, but
otherwise immune compromised such as patients with
solid organ or bone marrow transplantation or those
being treated for autoimmune disorders [6]. Cases of PBL
occurring in elderly, immune competent patients have
been documented and increasingly described in extra-oral
locations [1, 6, 7]. Extra-oral PBL has been reported in
various locations; however to the best of our knowledge,
PBL was never described within ovarian cystic teratoma.
This case is unusual as it presents the first described case
of PBL in a 19-year old, immune competent patient,
within the walls of a mature ovarian cystic teratoma, with
concurrent involvement of spleen, lymph nodes and breast
tissue. Primary NHL of the ovary is a relatively rare
occurrence while secondary involvement is much more
common [8]. Descriptions of NHL arising in mature cystic
teratoma are even more rare. There have only been a few
reports describing DLBC and follicular lymphoma arising
in a mature cystic teratoma [9–11]. Primary ovarian
lymphoma accounts for 0.5% of extranodal NHL and 1.5%
of primary ovarian cancers [12]. The existence of primary
ovarian NHL is a question of debate by some authors
because there is no pre-existing lymphoid tissue in the
ovaries for lymphoma to develop. However, some studies
have identified small number of lymphocytes around
blood vessels at the hilum and within epithelial structures
of teratomas, supporting the hypothesis for possible
development of primary ovarian lymphoma [13, 14] from
this lymphoid tissue. Also, due to varying definitions, the
existence of primary ovarian lymphoma remains debat-
able. Fox et al. proposed the following diagnostic criteria
for a primary ovarian lymphoma: 1. The lymphoma
should be confined to the ovary or at the maximum, to
the adjacent group of lymph nodes draining the organ
involved or if there has been direct infiltration of adjacent
structures while full investigation fails to reveal evidence
of lymphoma elsewhere; 2. The peripheral blood and bone
marrow should not contain any abnormal cells; 3. If
further lymphomatous lesions occur at sites remote from
the ovary, then at least several months should have
elapsed between the appearance of the ovarian and extra-
ovarian lesions [15]. According to this definition, our
patient’s PBL was disseminated, secondary disease with
concurrent involvement of the ovarian mature cystic
teratoma. Also, our patient presented with B symptoms as
a main complaint, which is more suggestive of secondary
involvement by PBL because the majority of patients with
primary ovarian lymphomas present with abdominal or
pelvic pain as their main complaint. Possible origin from a
teratoma with differentiation along hematopoietic cell
lines could be considered, but it is less likely and difficult
or impossible to prove.
EBV plays an important role in the tumorigenesis of PBL
with expression of EBER by in situ hybridization (ISH) in
82% and 46% of the HIV-positive and HIV-negative cases,
respectively [3]. The presence of plasmablasts is noted in
reactive processes, associated with viral infections, but
nevertheless pathogenesis of PBL is poorly understood.
In addition to EBV infection, recent studies have identified
the presence of MYC gene rearrangements as important
pathogenic mechanisms [16, 17]. Using ISH, Valera et al.,
examined a larger population of PBL patients and found
MYC rearrangement in 49% of the cases [18]. In PBL, MYC
deregulation, mediated by translocation or amplification
allows MYC to overcome the regulatory effects of BCL-6 or
BLIMP-1. BCL-6 is a repressor of MYC in the germinal
center B cells, whereas BLIMP-1 is a repressor of MYC in
Fig. 1 Macroscopic image of multiloculated ovarian cyst and spleen. a The right ovary was replaced by a cystic tumor (mature teratoma) with
multiple solid nodules of PBL within the cyst’s walls (arrows). b Spleen with multiple PBL nodules
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terminally differentiated B cells [2]. According to one theory,
MYC translocation may lead to the plasmablastic morph-
ology and create a more aggressive disease state [3, 19]. Also,
it has been observed that MYC rearrangements are more
often seen in EBV-positive compared to EBV-negative
tumors [18]. Therefore, we also performed c-MYC immu-
nohistochemistry which showed strong protein ex-
pression in >40% of tumor cells (Fig. 3). Furthermore,
to examine c-MYC gene status, fluorescent in situ
hybridization (FISH) was performed using Vysis MYC
Break Apart FISH Probe Kit (Abbott Molecular, IL,
USA) and Vysis LSI IGH/MYC, CEP 8 Tri-color Dual
Fusion Translocation Probe (Abbott Molecular, IL,
USA). We found 8q24 rearrangement within tumor
cells but we did not find specified t (8,14) IGH/MYC
translocation (Fig. 3).
The present case was negative for HIV and EBV
infection was not detected by ISH. Some studies
revealed that EBV infection was detected in only 17%
of HIV-negative PBL cases, suggesting that EBV is
not a distinct contributor in the pathogenesis of PBL
in patients without HIV infection [20, 21].
Fig. 2 Histology and immunohistochemisty of plasmablastic lymphoma. a Haematoxylin and eosin section shows monotonous, lymphoid cells with
“starry sky” pattern (magnification ×100). b Giemsa staining highlights the plasmablastic appearance with eccentrically positioned nuclei, prominent
nucleoli and abundant basophilic cytoplasm (magnification ×400). c-f Atypical lymphoid cells were negative for CD20 (c) and CD30 (e), while they
were positive for CD79a (d) and CD138 (f) (immunoperoxidase stain; c, d and e magnification × 400; f magnification ×200). g Nuclear proliferation rate,
assessed by Ki-67 was approximately 80% (immunoperoxidase stain; magnification × 200). h EBV encoded RNA (EBER) was negative in the nuclei of
the atypical cells (magnification ×400)
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The minimum morphologic criteria, required to diagnose
PBL, are monomorphic cellular proliferation of plasma-
blasts, with either centrally or eccentrically placed nuclei,
with high nuclear-cytoplasmic rate, a moderate amount of
eosinophilic cytoplasm, a high mitotic index and the
absence of plasma cells in the background [22, 23]. High
mitotic activity found in all PBLs as determined by Ki-67
proliferation index, is consistent with our case. PBL should
also be differentiated from other malignant diseases includ-
ing DLBCL, poorly differentiated carcinomas, melanoma,
gastrointestinal stromal tumors, Burkitt’s lymphoma and
anaplastic large cell lymphoma. However, the main differ-
ential diagnosis of PBL is plasmablastic or anaplastic
multiple myeloma. In practice the distinction between these
frequently depends on clinical correlation. HIV infection,
immune suppression and EBER positivity favor PBL diag-
nosis, while the presence of monoclonal paraproteinemia,
lytic bone lesions, hypercalcemia and renal dysfunction
favors a diagnosis of myeloma. Also high Ki-67 proliferation
index and CD56 positivity favors diagnosis of PBL over
myeloma [6].
PBL is a highly aggressive disease with the majority of
patients dying within the first year after initial presentation.
A systemic review of HIV-positive patients with PBL
showed a median overall survival (OS) of 15 months versus
9 months in HIV-negative patients [24]. Furthermore, very
high Ki-67 index andMYC gene rearrangements, have been
shown to be associated with shorter OS in patients with
PBL [2, 21]. Also extra-oral PBL are more frequently
disseminated at the time of diagnosis (57% of patients are
at stage IV) [21]. The prognostic value of EBV related anti-
gens expression in PBL cases is unclear. Some studies have
shown that EBV is not associated with outcome in HIV-
associated PBL while other studies have shown that EBV
infection correlated with better outcome in immune
competent patients [2]. In our case, the patient’s immune
competent, HIV-negative status, EBER negativity, extra-oral
location, high Ki-67 proliferation index and MYC
rearrangement were all predictors of the aggressive clinical
course and short survival.
PBL remains difficult to diagnose and to treat. A
standard therapeutic approach for patients with PBL has
not been established. In particular, the use of cyclophos-
phamide, doxorubicin, vincristine and prednisone
(CHOP) is considered inadequate therapy, and current
Fig. 3 MYC immunohistochemistry and fluorescent in situ hybridization
(FISH). a Large atypical plasmablasts were c-MYC positive in >40% of cells.
b FISH analysis using Vysis MYC Break Apart FISH Probe Kit revealed 8q24
rearrangement within tumour cells (cells without rearrangement should
have 2 yellow fusion signals; magnification × 1000). c FISH analysis using
Vysis LSI IGH/MYC, CEP 8 Tri-color Dual Fusion Translocation Probe is
negative for t(8,14), without yellow signals specific for IGH/MYC translocation
(normal 2 green (IgH) and 2 red (MYC, 8q24) signals); magnification × 1000
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guidelines recommend more intensive treatments [2].
Such treatments include infusional etoposide, vincristine
and doxorubicin with bolus cyclophosphamide and
prednisone (EPOCH), cyclophosphamide, vincristine,
doxorubicin, methotrexate alternating with ifosfamide,
etoposide and cytarabine (CODOX-M/IVAC) [25], or
hyperfractionated cyclophosphamide, vincristine, doxo-
rubicin, and dexamethasone alternating with methotrex-
ate and cytarabine (hyper-CVAD) [26]. More recently,
the role of stem cell transplantation (SCT) in patients
with PBL has been assessed [27]. It appears patients with
PBL with chemotherapy-sensitive disease might benefit
from autologous SCT in the first remission therefore, it
seems rational to explore the use of autologous SCT
earlier in the disease course [27]. Some studies have
reported that bortezomib (proteasome inhibitor) alone or
in combination with chemotherapy may have an antitumor
effect in PBL considering it has many morphologic and
immunophenotypic similarities with myeloma [28]. In our
case, the patient received 4 cycles of DA-EPOCH, followed
by 1 cycle of salvage DHAP and 4 cycles of alternating
modified CODOX-M/IVAC chemotherapy. Unfortunately
autologous SCTcould not be performed due to the patient’s
worsening clinical status.
Conclusions
In conclusion, we report a peculiar, extra-oral PBL case de-
tected within a mature cystic teratoma in an HIV-negative,
immune competent patient. To the best of our knowledge,
this is the first case of PBL described in a mature ovarian
cystic teratoma. Diagnosis of PBL is challenging, especially
when it arises in younger, HIV-negative, immune compe-
tent, female patients without EBER positivity. Currently
there is no definitive treatment regimen capable of provid-
ing curative results, therefore until standardized chemo-
therapy is identified, management of patients with PBL
should be on case to case basis [29].
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